<code id='0B64EF49D7'></code><style id='0B64EF49D7'></style>
    • <acronym id='0B64EF49D7'></acronym>
      <center id='0B64EF49D7'><center id='0B64EF49D7'><tfoot id='0B64EF49D7'></tfoot></center><abbr id='0B64EF49D7'><dir id='0B64EF49D7'><tfoot id='0B64EF49D7'></tfoot><noframes id='0B64EF49D7'>

    • <optgroup id='0B64EF49D7'><strike id='0B64EF49D7'><sup id='0B64EF49D7'></sup></strike><code id='0B64EF49D7'></code></optgroup>
        1. <b id='0B64EF49D7'><label id='0B64EF49D7'><select id='0B64EF49D7'><dt id='0B64EF49D7'><span id='0B64EF49D7'></span></dt></select></label></b><u id='0B64EF49D7'></u>
          <i id='0B64EF49D7'><strike id='0B64EF49D7'><tt id='0B64EF49D7'><pre id='0B64EF49D7'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:838
          foreign-trained health professionals
          Adobe

          The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

          The American Hospital Association, the industry’s main lobbying group, told STAT it is “not commenting on this issue right now.” The American Medical Association had no comment and deferred to other physician trade groups. The Federation of American Hospitals offered no statement.

          advertisement

          The American Health Care Association, which lobbies on behalf of nursing homes, did not comment on the list of 10 drugs or Medicare’s negotiating power. But it said in a statement that “many nursing home residents have multiple chronic conditions that require several medications, so any efforts at reducing their out-of-pocket costs would be welcome.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal
          Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more

          Smaller biotechs seek to piggyback on weight loss drug boom

          SuzanneKreiterGlobestaffThestate’scelebratedclusterofbiotechshashatchedbreakthroughmedicinesforevery